November 29, 2016 - By Marguerite Chambers
In a note released on Tuesday morning, Bioventix Plc (LON:BVXP) stock had its “Corporate” Rating maintained by expert analysts at finnCap. They currently have a GBX 1450.00 target price on company. finnCap’s target would suggest a potential upside of 5.45% from the company’s close price.
About 377 shares traded hands. Bioventix PLC (LON:BVXP) has risen 33.17% since May 2, 2016 and is uptrending. It has outperformed by 27.91% the S&P500.
Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The company has a market cap of 70.11 million GBP. The Firm is a biotechnology firm specializing in the development of high-affinity sheep monoclonal antibodies for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. It has a 19.55 P/E ratio. The Firm uses its technology in the fields of clinical diagnostics.
More important recent Bioventix PLC (LON:BVXP) news were published by: Fool.Co.Uk which released: “Why I Would Buy Bioventix Plc Over GlaxoSmithkline Plc And AstraZeneca Plc” on April 28, 2015, also Fool.Co.Uk published article titled: “Should I Invest In Bioventix PLC, Flybe Group PLC And Tasty Plc Now?”, Uk.Finance.Yahoo.com published: “-LSE Ticker: 4QVDF0/ISIN: GB00B4QVDF07” on April 10, 2010. More interesting news about Bioventix PLC (LON:BVXP) was released by: Fool.Co.Uk and their article: “3 Solid Small-Caps Set To Fly? Tasty Plc, Bioventix PLC And Alkane Energy Plc” with publication date: April 30, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.